Health Canada received a submission from GSK for RSV older adult vaccine candidates in adults aged ≥60yrs.
The submission includes the results from the P-III trial (AReSVi-006) evaluating the efficacy of a single dose of GSK’s adjuvanted RSVPreF3 older adult vaccine in adults aged ≥60yrs. in 25,000 patients against RSV-lower respiratory tract disease across 17 countries incl. Canada
If the RSV older adult vaccine candidate is approved, it will be the first vaccine to protect adults aged ≥60yrs. from lower respiratory tract disease caused by RSV inf.
Ref: GSK | Image: GSK